Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price37.01 USD
Fair value47.50
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-02Read Markdown38.27-3.3% to today ✓Accumulation gives way to Markdown first Markdown read since July
2026-09-13Read Accumulation39.00-5.1% to today Markup gives way to Accumulation
2026-08-13Read Markup39.05-5.2% to today Markdown gives way to Markup after an 11% rise in 6 weeks
2026-07-02Read Markdown35.05+5.6% to today First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Sonida Senior Living, Inc. holds its Markdown at $37.01. The statistical read favours the sellers, held for 17 days.
As held on the ledger · 2026-11-04
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 17 days
Price at the screen
$37.01
Valuation
N/A trailing · -22.43 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.89
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
81.64%
Below 33%
Interest-bearing debt is 81.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
3.51%
Below 49%
Money owed to the company is 3.5% of assets, under the 49% limit.
Pass
Revenue purity
0.55%
Below 5%
Only 0.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Sonida Senior Living,'s business is in a permissible area, but its interest-bearing debt is about 82% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SNDA's ethical verdict changes
Today SNDA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 22% discount to our $47.50 fair value, 137.10% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 22.1% discount to the base estimate.
Where our models see it going: fair-value estimate $47.50, with a range of $43.00 to $65.00, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Senior homes operator grows fast but stays loss making
Picture a care home chain racing to add residents and fill beds while still losing money on almost every one of them. Sonida shows 38 percent revenue growth yet posts a 27 percent negative profit margin and a 20 percent negative return on equity. At a forward multiple of minus 92 times it is priced for a recovery that has not appeared in the numbers, and our fair value sits just below the current share price.
The business clears our ethical screen, but that is not enough to create an opportunity. Four analysts see the shares worth around the same level they trade at today, leaving no meaningful margin of safety. Unknown competitive position and continued cash burn mean any improvement must come from higher occupancy and tighter costs, neither of which is guaranteed.
Senior living remains exposed to labour shortages, rising wages and shifts in resident demand. A single downturn in occupancy could widen losses quickly. The market is already assuming a turnaround that the reported results have yet to deliver.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SNDA trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markdown$37.01+8.7%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 8.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markdown$34.04-0.8%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markdown$34.30+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markdown$34.30+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markdown$34.30+1.4%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markdown$33.82+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markdown$33.82+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markdown$33.82+1.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$33.47-6.5%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it buy, with a mean price target of $40.
2026-10-18Markdown$35.79-6.5%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it buy, with a mean price target of $40.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
